Harmos Horton Lusk is pleased to be advising NZX/ASX listed Pacific Edge Limited on its $21 million equity capital raise by way of a placement to selected investors and a share purchase plan. The placement, which was undertaken on 30 May 2025, was oversubscribed and raised $16 million, subject to shareholder approval which will be sought in July or August this year. The share purchase plan is expected to launch in July or August and is intended to raise up to $5 million of additional equity capital (subject to Pacific Edge’s ability to accept oversubscriptions).
Pacific Edge is a global cancer diagnostics company leading the way in the development and commercialisation of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
The Harmos Horton Lusk team that is advising on the transaction is led by directors Nathanael Starrenburg and Tim Mitchelson, and includes associate Tallara Daldorf.